DGAP-News: Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis
Apricus Biosciences, Inc.
11.05.2012 15:55
—————————————————————————
SAN DIEGO, 2012-05-11 15:55 CEST (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Health Canada has granted the
Company–s request for a Pre-New Drug Submission (–Pre-NDS–) meeting to obtain
regulatory guidance from the agency for MycoVa(tm), the Company–s topical
treatment for
